Gilenya is the first approved once-daily oral therapy for the treatment of relapsing forms of multiple sclerosis (MS). It was observed in the study that Gilenya was effective against key measures of ...

U.S. health regulators said on Tuesday they received a report of a multiple sclerosis patient who died within 24 hours of taking the first dose of Novartis AG's Gilenya. The U.S. Food and Drug ...

The FDA has approved Gilenya (fingolimod capsules, from Novartis), a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to ...

The digital press release with multimedia content can be accessed here: Basel, April 29, 2014 - Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a ...

The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...

After handing Novartis a win in January, a U.S. appeals court has changed course in a Gilenya patent infringement lawsuit. On Tuesday, the judges revived a Chinese drugmaker’s bid to challenge the ...

EMA has issued a recommendation that the multiple sclerosis drug, Gilenya (fingolimod), not be used in women who are pregnant. The European Medicines Agency (EMA) has issued a recommendation that the ...

After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court. Wednesday, Novartis said it plans to petition the Supreme ...

Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya ® (fingolimod) for the treatment of ...

If you have a certain type of multiple sclerosis (MS), your doctor might suggest Gilenya (fingolimod) as a treatment option for you. Gilenya is a prescription medication that’s used to treat the ...

ZURICH, March 21 (Reuters) - Swiss drugmaker Novartis AG said the European Commission approved its multiple sclerosis pill Gilenya, a potential blockbuster that should help it cope with price ...

EXTON, Penn.--(BUSINESS WIRE)-- BioTrends Research Group, LLC finds that, while surveyed neurologists are almost unanimous in reporting that the unique mode of administration of Novartis’s Gilenya is ...